KOLKATA LIVER MEETING Dec, 2016 Theme: Emerging Therapeutics in Liver Disease

		Time (mins)	Speaker
hursday, 1st December, 2016			
lst December 1300 - 1400 pm	LUNCH		
.400 pm - 15 30 pm	Emerging paradigms		
	Cirrhosis: prospects of modifying the disease, beyond etiology specfic		
	interventions	20	Scott Friedman
	Acute Liver failure: Innovations in therapy	20	Patrick Kamath
	Systemic Inflammation as a target for therapy in liver diseases	20	Rajiv Jalan
	Interventions targeting Gut Microbiota in liver disease: Progress and prospects	20	Jasmohan Bajaj
	Discussion	10	
5:30 - 16:00	Session 2: Clinical Case Discussion		
	Development of HCC in HBV infection despite antiviral therapy	30	Manoj Kumar
.6:00 - 16: 30	COFFEE		
6:30 - 18 : 00	Session 3: HBV therapy		
	Novel HBV antiviral drug targets - an expanding Pipe Line		Henry Chan
	Emerging Immunological Approaches to HBV therapy	20	S M F AKBAR
	Immune tolerant HBV and Low viral load infections beyond guidelines - therapy		
	plan		Shyam Kotilil
	Prevention of Mother to child transmission - options and promise	20	Calvin Pan
	Discussion	10	
18: 00 - 19-10 pm	Session 4: Conduct of Clinical Trials		
	The art and Science of Picking up drug targets and the earlier phases of drug	20	Jun Sonoda
	Phase 3 trials ;organisation and implementation	20	Mani Subramanian
	Clinical Trial Regulations in India -	20	DCGI
	Discussion	10	
9 - 30 pm on wards	DINNER		
riday 2nd December , 2016			
09:00 - 10:10	Session 5 : Trends in Organ Dysfunction in Cirrhosis		
	Management of renal dysfunction in Cirrhosis: What's New?	20	Pere Gines
	Evolving pharmaceutical modifiers of Portal Hypertension: How they could fit	_	
	into clinical practise	20	Patrick Kamath
	Heaptic Encephalopathy: New therapy Approaches and its' impact	20	Jas mohan Bajaj

KOLKATA LIVER MEETING Dec, 2016 Theme: Emerging Therapeutics in Liver Disease

		Time	
		(mins)	Speaker
	Discussion	10	
10:00 - 11:30	Session 6: Management of Acute on Chronic Liver failure		
	A case of HBV flare , diabetes and ACLF	20	Shiv Sarin
	A case of Alcoholic hepatitis and ACLF	20	Rajiv Jalan
	Intensive care issues in ACLF management	15	Patric Kamath
	"Critically ill Cirrhotic" and "Acute on Chronic Liver Failure": The only issue is		
	semantics - a Cross Cutting View	15	Subrat Acharya
	Discussion	10	
11:30 - 12 :00	COFFEE		
1200- 12 -45 pm	Session 7: Innovations in Cell therapy and Support Systems		
	Approaches to Cell therapy in Liver failure		Jayanta
		20	Roychowdhury
	Liver support devices and bioengineered platforms as innovative tools	20	Rakhi Maiwall
	Discussion	5	
12:45 - 13 30 pm A K BASU	MEMOR A. K. Basu Memorial Oration	45	John Martin
13:30 to 14:00	LUNCH		
14:00 - 15:45	Session 8: NASH - The EXPANDING HORIZON		
	Pathophysiological basis for Pharmacological innovations in NASH	15	Rohit Loomba
	Weight reduction, lifestyle modifications and bariatric surgery - the traditionals		
			Ajay Duseja
	Drugs targeting inflammation and fibrosis in NASH		Mani Subramanian
	DPP 4 and GLP 1 modifiers IN NASH		Ashwani Singhal
	Nuclear Recpetor modulation and NASH therapy		shalimar
	How I treat NASH now and How I will in 2017	20	Rohit Loomba
	Discussion	10	
<mark>15:45 - 16 -45 PM Autoim</mark>	nmune Liv Session 9 : Autoimmune Liver Diseases		
	New therapies in PBC	20	Giddeon hirschfield
	When and How to stop therapy in AIH	15	Vivek Sarawat
	Evolving Therapy of IGG4 Disease	20	Giddeon Hirschfield
	Discussion	5	
16 45 pm to 17 00 pm	Coffee break		
17:00- 18:00	Session 11: Alcoholic Hepatitis - Emerging Frontiers		

KOLKATA LIVER MEETING Dec, 2016 Theme: Emerging Therapeutics in Liver Disease

	Therapeutics in Liver Disease		
		Time	
		(mins)	Speaker
	Novel anti inflammatory approaches in alcoholic hepatitis	20	Philip Mathurin
	Sepsis in alcoholic hepatitis: Immunomodulation and its' outcome	20	Shiv Sarin
	A "sick" alcoholic hepatitis patient : ways to salvage	20	Ashwani Sighal
	Discussion	5	
18:00 - 19:00	Session 12: HCV therapy - REMNANT ISSUES		
	Therapy in the setting of Compromised Renal Function	15	Sameer Shah
	DAA FAILURE and Relapses	15	Shyam Kotilil
	Approaching HCV as a Public Health Issue: Punjab Experience	15	R K Dhiman
	Any window for another New drug for HCV in 2017 and beyond?	15	Mani Subramanian
	Discussion	5	
20:00 - onwards	DINNER		
Saturday 3rd December, 20	016		
09:00 - 10:15	Session 13: HCC		
	Multi disciplinary HCC care - the new era	20	Maria Reig
	Advanced HCC - therapeutic options and innovations	15	Swastik Agarwal
	Liver transplantation in HCC	15	Subash Gupta
	Progress and challenges in Organised HCC care in India	15	Subrat acharya
10:15 - 11 30 am Session 14:	Session 14: Metabolic , Drug Induced Cholestatic disease		
	Mangement of Wilson's Disease - New paradigms	25	M Schilsky
	Drug Induced Liver Disease: Any therapy modifying course?		
		20	Harshad Devarbhavi
	Emerging approaches to management of Familial Cholestasis	20	Ujjal Poddar
	Discussion	5	
11 30 - 11 45 am : Session 15	COFFEE		
11: 45 - 13 50 PM :	Session 15: Future Perspective		
	Anti fibrotic Drug Development entering an exciting era	20	S Friedman
	Management of Acutely III cirrhotic : the ways the story will unfold	20	Pere Gines
	Hepatocellular Cancer: Molecules and outcome in the next 5 years	20	Maria Reig
	Emerging biomarkers in Liver Disease : the aura / era of Personalised liver		
	disease care	20	Rohit Loomba

	KOLKATA LIVER MEETING Dec, 2016 Theme: En	nerging	
	Therapeutics in Liver Disease		
		Time	
		(mins)	Speaker
13:30 onwards	Lunch and Closure		
13:30 onwards	Lunch and Closure	(IIIIIIs)	эреакег